国健呈诺生物科技

Guojian Chengnuo is a clinical-stage biotechnology company based in Beijing, China, specializing in the development of induced pluripotent stem cell (iPSC) derived therapies. The company focuses on creating off-the-shelf immune cell products, particularly CAR-NK cells, to treat a variety of solid tumors and hematological malignancies. Their lead programs include iPSC-derived CAR-NK cells targeting mesothelin for advanced solid tumors like ovarian cancer and mesothelioma. By leveraging their proprietary iPSC platform, Guojian Chengnuo aims to overcome the limitations of autologous cell therapies, such as high costs and manufacturing complexity. The company has successfully advanced multiple candidates into clinical trials, positioning itself as a leader in the Chinese iPSC-based regenerative medicine and oncology space. Their manufacturing capabilities include a large-scale GMP facility designed for standardized production of cell products.